Specifically, AMG510 (also known as sotorasib) is the first G12Ci approved by the US Food and Drug Administration (FDA) in 2021 for the treatment of adult patients with KRAS-G12C–mutated NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.